MHC I级
免疫疗法
抗原
卵清蛋白
树突状细胞
癌症免疫疗法
免疫学
交叉展示
抗原呈递
细胞毒性T细胞
抗原处理
MHC II级
主要组织相容性复合体
癌症研究
医学
T细胞
免疫系统
生物
生物化学
体外
作者
Ryo Suzuki,Yusuke Oda,Naoki Utoguchi,Eisuke Namai,Yuichiro Taira,Naoki Okada,Norimitsu Kadowaki,Tetsuya Kodama,Katsuro Tachibana,Kazuo Maruyama
标识
DOI:10.1016/j.jconrel.2008.10.015
摘要
In dendritic cell (DC)-based cancer immunotherapy, it is important that DCs present peptides derived from tumor-associated antigens on MHC class I, and activate tumor-specific cytotoxic T lymphocytes (CTLs). However, MHC class I generally present endogenous antigens expressed in the cytosol. We therefore developed an innovative approach capable of directly delivering exogenous antigens into the cytosol of DCs; i.e., a MHC class I-presenting pathway. In this study, we investigated the effect of antigen delivery using perfluoropropane gas-entrapping liposomes (Bubble liposomes, BLs) and ultrasound (US) exposure on MHC class I presentation levels in DCs, as well as the feasibility of using this antigen delivery system in DC-based cancer immunotherapy. DCs were treated with ovalbumin (OVA) as a model antigen, BLs and US exposure. OVA was directly delivered into the cytosol but not via the endocytosis pathway, and OVA-derived peptides were presented on MHC class I. This result indicates that exogenous antigens can be recognized as endogenous antigens when delivered into the cytosol. Immunization with DCs treated with OVA, BLs and US exposure efficiently induced OVA-specific CTLs and resulted in the complete rejection of E.G7-OVA tumors. These data indicate that the combination of BLs and US exposure is a promising antigen delivery system in DC-based cancer immunotherapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI